Amylin Pharmaceuticals LLC

Amylin Pharmaceuticals — Proxy Contest (May 2009)

7 slides from Amylin Pharmaceuticals's proxy contest presentation, May 11, 2009

  1. Slide 1: Icahn Influence on Biotechnology Boards: Setting the Record Straight

    Icahn Influence on Biotechnology Boards: Setting the Record Straight Spring 2009

  2. Slide 2: Legal Information

    Legal Information FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about Amylin. Our actual results could differ materially from those discussed due to a number of factors, including: BYETTA, SYMLIN or exenatide once weekly being affected by competition, safety or oth

  3. Slide 3: Debunking Icahn's Assertions

    Debunking Icahn’s Assertions Critical that investors understand what actually happens when Icahn gains representation on biotechnology Boards Operational disappointments Lagging share price performance Focus on sale Prior to the sale of the company, ImClone was not the success story that Icahn claim

  4. Slide 4: ImClone's Value after Icahn Reps on Board

    ImClone’s Value after Icahn Reps on Board ImClone’s royalty rate on Erbitux has remained unchanged at 39% since 2002, when it signed the initial Bristol collaboration agreement Icahn’s Claim Fact “Re-charged Partner Relations” “Increased Erbitux Sales” Merck KGaA nearly tripled ex-U.S. sales from $2

  5. Slide 5: The Inconvenient Truth Behind Icahn's "Cost Controls"

    Increase in Royalty Revenues Increase in Other Revenues Increase in SG&A Increase in Other Operating Expenses Net Change in EBITDA Increase in R&D Reduction in CAPEX Net Change in Free Cash Flow Icahn touted that “Tighter Cost Controls Contributed to Higher Cash Flow” at ImClone ImClone costs increa

  6. Slide 6: A Series of Operational Disappointments

    A Series of Operational Disappointments $ Volume (MM) 5/2/06 8/24/06 12/19/06 4/13/07 8/8/07 12/3/07 3/27/08 7/22/08 11/14/08 Volume Earnings Miss Price Revenue Guidance Down ImClone consistently underperformed Wall Street expectations during Denner’s tenure Growth in EPS was substantially driven by

  7. Slide 7: Adventrx: Icahn's Other Biotech Board Experience

    Adventrx: Icahn's Other Biotech Board Experience $ Volume (MM) 8/12/05 8/12/06 8/12/07 8/12/08 5/8/09 Volume Price Presiding over significant value destruction 8/12/05 Adventrx appointed Keith Meister to its Board, increasing Board membership from 5 to 6. Mr. Meister was nominated by Carl Icahn 5/8/

Amylin Pharmaceuticals — Proxy Contest (May 2009) on 6ix